Tirzepatide Who Should (and Shouldn’t) Take It: Eligibility & Contraindications

Introduction

Tirzepatide has three FDA-approved indications as of 2026: type 2 diabetes (Mounjaro®), chronic weight management in adults with BMI 30+ or BMI 27+ with a comorbidity (Zepbound®), and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, expanded indication December 2024).

Beyond the labels, clinicians prescribe tirzepatide off-label for prediabetes, metabolic syndrome, polycystic ovary syndrome, fatty liver disease, and other metabolic conditions. Compounded tirzepatide is prescribed under personalized assessment without rigid label restrictions.

Eligibility isn’t just about who can benefit. Absolute contraindications include personal or family history of medullary thyroid cancer, Multiple Endocrine Neoplasia type 2 (MEN 2), prior severe hypersensitivity to tirzepatide, pregnancy, and breastfeeding. Several other conditions warrant caution or modified dosing.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Who Is Eligible for Tirzepatide for Weight Loss?

The Zepbound label covers adults with BMI 30 kg/m² or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity. Qualifying comorbidities include type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, cardiovascular disease, and others.

Quick Answer: FDA approved for BMI 30+ or BMI 27+ with a comorbidity for weight loss

Pediatric eligibility for tirzepatide is more limited than semaglutide. SURMOUNT-PED is the ongoing trial in adolescents. As of 2026, tirzepatide isn’t FDA-approved for use under age 18, though off-label pediatric use occurs.

Commercial insurance often layers additional requirements: documented prior weight loss attempts, dietary counseling enrollment, or step therapy through older drugs. These are insurance rules, not FDA requirements.

Who Is Eligible for Tirzepatide for Diabetes?

Mounjaro is approved for adults with type 2 diabetes as add-on to diet and exercise to improve glycemic control. There’s no BMI requirement for the diabetes indication. Patients with HbA1c above target on metformin or other first-line agents are typical candidates.

Mounjaro isn’t currently FDA-approved for cardiovascular risk reduction in diabetic patients, unlike Ozempic®. The SURPASS-CVOT trial is expected to read out in 2026 or 2027, which may extend the label.

For patients with both diabetes and obesity, clinicians can prescribe either Mounjaro or Zepbound. Insurance coverage often determines which label is used.

Who Is Eligible for Tirzepatide for OSA?

Zepbound was approved for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024 based on SURMOUNT-OSA (Malhotra et al. 2024, NEJM). Eligibility requires BMI 30 or higher and documented moderate-to-severe OSA (typically AHI 15 or higher).

The OSA indication is meaningful because it’s the first pharmacologic treatment for OSA. CPAP remains the gold standard but is poorly tolerated by many patients. Tirzepatide offers an alternative or adjunct.

Medicare covers Zepbound for the OSA indication, which was a notable change from the standard “no weight loss drugs” rule. The OSA pathway has become a coverage route for many patients who couldn’t get weight loss approval.

When Should Tirzepatide Not Be Used?

Absolute contraindications per the FDA label:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity reaction to tirzepatide or any product component
• Pregnancy
• Type 1 diabetes (tirzepatide is not insulin and isn’t a substitute)

The MTC contraindication comes from rodent studies showing C-cell tumors at high doses. The relevance to humans is debated, but the FDA labeling remains conservative. Family history alone is enough to exclude a patient.

Breastfeeding is listed as a precaution rather than an absolute contraindication, but most clinicians avoid tirzepatide during lactation due to limited safety data.

What About Pregnancy and Contraception?

Tirzepatide is contraindicated in pregnancy. Animal studies showed reproductive toxicity at clinically relevant doses. Patients of childbearing potential should use reliable contraception while taking tirzepatide and for 1 to 2 months after the last dose before attempting pregnancy.

Oral contraceptive efficacy may be slightly reduced by delayed gastric emptying, particularly during dose escalation. Eli Lilly explicitly recommends a backup contraceptive method or an alternative non-oral contraceptive for 4 weeks after starting tirzepatide and 4 weeks after each dose escalation.

For patients planning pregnancy, tirzepatide should be stopped at least 1 to 2 months before attempting conception. There’s no evidence that prior tirzepatide use causes long-term reproductive harm, but timing the discontinuation gives the drug time to fully clear.

What Conditions Require Caution?

Relative contraindications (caution, not absolute):

• Severe gastroparesis (delayed gastric emptying disease)
• History of pancreatitis
• Severe gastroesophageal reflux disease
• Active gallbladder disease
• Severe hepatic impairment (limited data)
• Eating disorders, especially anorexia nervosa
• Recent bariatric surgery (within 6 months)
• Chronic kidney disease stage 4 or 5 (close monitoring needed)

Gastroparesis is the most consistent caution because tirzepatide directly slows gastric emptying. Prior pancreatitis is a relative contraindication based on theoretical risk.

What About Age Limits?

The lower limit is 18 years for tirzepatide as of 2026 (no pediatric approval yet). The upper limit isn’t specified by the FDA, but caution applies to older adults due to higher risk of dehydration, falls, kidney injury, and drug interactions.

Patients over 75 face higher risk from GI side effects. Vomiting and diarrhea can cause more rapid dehydration than in younger patients. Slower titration and closer monitoring are standard.

Sarcopenia is a concern in older adults losing weight. The fraction of lean mass loss is often higher in patients with low baseline muscle mass. Resistance training and adequate protein intake (~1.0 to 1.2 g/kg/day) are particularly important.

Who Shouldn’t Use Tirzepatide for Weight Loss Specifically?

Beyond the FDA contraindications, tirzepatide for weight loss isn’t appropriate for:

• Adults with BMI under 27 (no medical indication)
• Patients with active eating disorders, especially restrictive subtypes
• Patients with depression or other mental health conditions where weight loss could worsen symptoms
• Athletes or active patients where the rapid weight loss would compromise performance (case-by-case)
• Patients who can’t reliably access medical follow-up for monitoring

The off-label use for cosmetic weight loss in non-overweight patients is increasingly common but not supported by safety or efficacy data.

Key Takeaway: Contraindicated with personal/family medullary thyroid cancer or MEN 2

What Baseline Tests Are Recommended?

Standard baseline workup before starting tirzepatide includes:

• Complete metabolic panel (kidney and liver function, electrolytes)
• HbA1c if diabetic or prediabetic
• Fasting lipid panel
• TSH for thyroid function
• Pregnancy test for patients of childbearing potential
• Baseline eye exam for diabetic patients

History should cover personal and family history of thyroid cancer, MEN 2, pancreatitis, gallbladder disease, eating disorders, mental health, and current medications. Drug-drug interaction screening matters, especially for patients on insulin, sulfonylureas, warfarin, or oral contraceptives.

Some clinicians order baseline lipase, amylase, and liver enzymes. These aren’t strictly necessary but provide comparison points if abdominal symptoms develop later.

What’s the Surgery Protocol?

Recent ASA guidance recommends holding GLP-1 medications including tirzepatide for at least one week before elective surgery due to gastric emptying effects and aspiration risk under anesthesia. Some institutions extend the hold to two weeks for upper GI procedures.

For emergency surgery, the anesthesia team uses rapid sequence induction techniques and treats the patient as having a full stomach regardless of fasting time. Routine endoscopy may also require holding the drug.

Resuming tirzepatide post-operatively typically waits until the patient is tolerating oral intake well and is past the immediate post-surgical period (usually 1 to 2 weeks). Restarting at the same dose is usually fine if the gap is under 4 weeks.

How Do You Assess Eligibility Through Telehealth?

Telehealth assessment for tirzepatide includes a detailed medical history questionnaire, weight and BMI verification, photo or video confirmation of identity, and review of contraindications and red flags. Many platforms require recent lab work or arrange for it through partner labs.

TrimRx uses a free assessment quiz that screens for contraindications and gathers the medical history needed for clinician review. If eligible, the patient is matched with a licensed provider who reviews the case and creates a personalized treatment plan.

Patients with significant comorbidities or complex medication regimens often benefit from in-person care. Telehealth works best for relatively straightforward cases where ongoing monitoring can be done through self-reporting and periodic labs.

Who Should Start with Tirzepatide vs Semaglutide?

Patients targeting weight loss above 20% may benefit from tirzepatide given SURMOUNT-1’s 20.9% loss vs STEP 1’s 14.9% for semaglutide. The dual GIP/GLP-1 mechanism produces larger effect.

Patients with type 2 diabetes who haven’t reached HbA1c targets on semaglutide often switch to tirzepatide. SURPASS-2 showed larger HbA1c and weight reductions with tirzepatide vs semaglutide 1 mg.

Patients with strong cardiovascular indications (established CAD, prior MI) currently have stronger evidence for semaglutide due to the SELECT trial. Tirzepatide’s cardiovascular evidence awaits SURPASS-CVOT results.

Patients with OSA have a unique reason to choose tirzepatide given the FDA OSA indication and the SURMOUNT-OSA trial data. Insurance coverage for OSA may favor tirzepatide.

What About Athletes and Active Patients?

Patients with high training volume or competitive athletic goals face unique considerations on tirzepatide. The appetite suppression can interfere with adequate fueling for training. Some athletes report decreased recovery and performance during the active loss phase.

For weight-class athletes looking to make weight, tirzepatide is generally not recommended due to rapid loss patterns that don’t align with competitive timelines and the risk of compromised performance during competition prep.

Recreational exercisers and patients pursuing weight loss for general health usually do well on tirzepatide with attention to protein, hydration, and resistance training. The drug doesn’t interfere with strength gains when adequate protein is consumed.

How Does Eligibility Differ From Semaglutide?

The BMI and comorbidity criteria for tirzepatide weight loss are identical to semaglutide. The key additional indication is OSA, which tirzepatide has but semaglutide doesn’t. Patients with documented OSA and obesity have a unique pathway to coverage with tirzepatide.

Tirzepatide doesn’t have semaglutide’s cardiovascular risk reduction indication yet. For patients with established CVD whose insurance requires an approved indication, semaglutide is the better starting point until SURPASS-CVOT results emerge.

Pediatric eligibility differs. Semaglutide is approved down to age 12. Tirzepatide isn’t approved under 18 as of 2026. SURMOUNT-PED is the ongoing adolescent trial.

Bottom line: Should be stopped at least one week before elective surgery per ASA guidance

FAQ

Can I Take Tirzepatide If I Have a Family History of Any Thyroid Cancer?

Only medullary thyroid cancer and MEN 2 are contraindications. Other thyroid cancers (papillary, follicular, anaplastic) don’t trigger the warning. If unclear, a thyroid ultrasound and calcitonin level can help establish that there’s no current concern.

Is BMI 26 with Diabetes Enough to Qualify for Zepbound?

No, the BMI 27 cutoff with comorbidity is firm in the FDA label. However, Mounjaro for diabetes has no BMI requirement, so a diabetic patient with BMI 26 can usually access tirzepatide that way.

Can I Take Tirzepatide While Breastfeeding?

The label lists it as a precaution rather than an absolute contraindication. Limited human data exist on transfer into breast milk. Most clinicians recommend avoiding tirzepatide during active breastfeeding.

What If I Have a History of Bulimia or Binge Eating Disorder?

Binge eating disorder may improve on tirzepatide, with reduced binge episodes seen in some patients. Active bulimia or anorexia nervosa is generally a contraindication because weight loss isn’t an appropriate goal and the medication can worsen restrictive patterns.

Can I Take Tirzepatide If I’ve Had Bariatric Surgery?

Yes, often. Patients who regain weight after sleeve gastrectomy or gastric bypass commonly use tirzepatide as an adjunct. Waiting at least 6 months post-operatively is typical to allow surgical healing and initial weight loss to stabilize.

Is Hypothyroidism a Problem?

No. Hypothyroidism on stable thyroid replacement is not a contraindication. Some clinicians check TSH after significant weight loss because dose adjustments may be needed.

What If I’m on Warfarin or Blood Thinners?

Tirzepatide can change the absorption of orally co-administered medications because of delayed gastric emptying. Patients on warfarin should monitor INR more frequently during titration. Direct oral anticoagulants are generally less affected.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.